Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study

T. Blažek, M. Petráš, P. Hurník, P. Matoušek, L. Knybel, ZZ. Čermáková, J. Štembírek, J. Cvek, R. Soumarová

. 2024 ; 14 (-) : 1346793. [pub] 20240404

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013062

INTRODUCTION: In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. METHODS: To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023. We focused on the expression of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) relative to overall survival (OS) and specific survival rates. Associations between biomarkers and survival rates were assessed by crude and adjusted hazard ratios (cHR, aHR, respectively) obtained from Cox proportional hazards regression. RESULTS: Among a total of 55 patients within a median follow-up of 19.7 months, there were 21 (38.2%) all-cause deaths and 15 (27.3%) cancer-related deaths. An overall survival (OS) rate of 61.8% and a disease-specific survival (DSS) rate of 72.7% were recorded. A significant association between survival rates and a ≥10% difference in PD-L1 expression on immune versus tumor cells (high PD-L1IC expression) was documented regardless of the type of analysis (univariate or multivariate). In addition, a stronger association was confirmed for OS and the composite biomarker high PD-L1IC expression along with either median-higher CD8+ TIL count or increased TIL density ≥30%, as indicated by an aHR of 0.08 (95% CI, 0.01 to 0.52) and 0.07 (95% CI, 0.01 to 0.46), respectively. Similar results were demonstrated for other specific survival rates. DISCUSSION: The early outcomes of the present study suggest the utility of a strong prognostic factor involving a composite biomarker high PD-L1IC expression along with increased TIL density in HNSCC patients undergoing definitive radiotherapy and radiochemotherapy. TRIAL REGISTRATION: The study is registered with Clinicaltrials.gov. - NCT05941676.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013062
003      
CZ-PrNML
005      
20250422074824.0
007      
ta
008      
240723e20240404sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2024.1346793 $2 doi
035    __
$a (PubMed)38638854
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Blažek, Tomáš $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study / $c T. Blažek, M. Petráš, P. Hurník, P. Matoušek, L. Knybel, ZZ. Čermáková, J. Štembírek, J. Cvek, R. Soumarová
520    9_
$a INTRODUCTION: In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. METHODS: To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023. We focused on the expression of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) relative to overall survival (OS) and specific survival rates. Associations between biomarkers and survival rates were assessed by crude and adjusted hazard ratios (cHR, aHR, respectively) obtained from Cox proportional hazards regression. RESULTS: Among a total of 55 patients within a median follow-up of 19.7 months, there were 21 (38.2%) all-cause deaths and 15 (27.3%) cancer-related deaths. An overall survival (OS) rate of 61.8% and a disease-specific survival (DSS) rate of 72.7% were recorded. A significant association between survival rates and a ≥10% difference in PD-L1 expression on immune versus tumor cells (high PD-L1IC expression) was documented regardless of the type of analysis (univariate or multivariate). In addition, a stronger association was confirmed for OS and the composite biomarker high PD-L1IC expression along with either median-higher CD8+ TIL count or increased TIL density ≥30%, as indicated by an aHR of 0.08 (95% CI, 0.01 to 0.52) and 0.07 (95% CI, 0.01 to 0.46), respectively. Similar results were demonstrated for other specific survival rates. DISCUSSION: The early outcomes of the present study suggest the utility of a strong prognostic factor involving a composite biomarker high PD-L1IC expression along with increased TIL density in HNSCC patients undergoing definitive radiotherapy and radiochemotherapy. TRIAL REGISTRATION: The study is registered with Clinicaltrials.gov. - NCT05941676.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petráš, Marek $u Third Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Hurník, Pavel $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Pathology, Ostrava University Hospital, Ostrava, Czechia
700    1_
$a Matoušek, Petr, $d 1973- $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Otorhinolaryngology, Ostrava University Hospital, Ostrava, Czechia $7 xx0068189
700    1_
$a Knybel, Lukáš $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
700    1_
$a Čermáková, Zuzana Zděblová $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
700    1_
$a Štembírek, Jan $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia $u Department of Orofacial Surgery, Ostrava University Hospital, Ostrava, Czechia
700    1_
$a Cvek, Jakub $u Department of Oncology, Ostrava University Hospital, Ostrava, Czechia $u Faculty of Medicine, University of Ostrava, Ostrava, Czechia
700    1_
$a Soumarová, Renata $u Third Faculty of Medicine, Charles University, Prague, Czechia $u Department of Oncology, Královské Vinohrady University Hospital, Prague, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 14 (20240404), s. 1346793
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38638854 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20250422074826 $b ABA008
999    __
$a ok $b bmc $g 2125585 $s 1224925
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c - $d 1346793 $e 20240404 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20240723

Find record

Citation metrics

Archiving options